BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 14521406)

  • 21. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3D-QSAR study of ring-substituted quinoline class of anti-tuberculosis agents.
    Nayyar A; Malde A; Jain R; Coutinho E
    Bioorg Med Chem; 2006 Feb; 14(3):847-56. PubMed ID: 16214351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of new CoMFA and CoMSIA 3D-QSAR models for anti-inflammatory phthalimide-containing TNFalpha modulators.
    Avila CM; Romeiro NC; da Silva GM; Sant'Anna CM; Barreiro EJ; Fraga CA
    Bioorg Med Chem; 2006 Oct; 14(20):6874-85. PubMed ID: 16843662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three-dimensional QSAR analyses of 1,3,4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors.
    Zhuo Y; Kong R; Cong XJ; Chen WZ; Wang CX
    Eur J Med Chem; 2008 Dec; 43(12):2724-34. PubMed ID: 18538451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacophore-based 3D-QSAR of HIF-1 inhibitors.
    Chung JY; Pasha FA; Cho SJ; Won M; Lee JJ; Lee K
    Arch Pharm Res; 2009 Mar; 32(3):317-23. PubMed ID: 19387572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
    Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
    Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
    Doddareddy MR; Cho YS; Koh HY; Pae AN
    Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors.
    Castilho MS; Postigo MP; de Paula CB; Montanari CA; Oliva G; Andricopulo AD
    Bioorg Med Chem; 2006 Jan; 14(2):516-27. PubMed ID: 16203153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
    Bhongade BA; Gouripur VV; Gadad AK
    Bioorg Med Chem; 2005 Apr; 13(8):2773-82. PubMed ID: 15781388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three-dimensional quantitative structure-activity relationship of interleukin 1-beta converting enzyme inhibitors: A comparative molecular field analysis study.
    Kulkarni SS; Kulkarni VM
    J Med Chem; 1999 Feb; 42(3):373-80. PubMed ID: 9986707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
    Cappellacci L; Franchetti P; Vita P; Petrelli R; Lavecchia A; Jayaram HN; Saiko P; Graser G; Szekeres T; Grifantini M
    J Med Chem; 2008 Jul; 51(14):4260-9. PubMed ID: 18588281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 3D-QSAR and molecular docking studies of benzaldehyde thiosemicarbazone, benzaldehyde, benzoic acid, and their derivatives as phenoloxidase inhibitors.
    Xue CB; Zhang L; Luo WC; Xie XY; Jiang L; Xiao T
    Bioorg Med Chem; 2007 Mar; 15(5):2006-15. PubMed ID: 17258462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural investigation of PAP derivatives by CoMFA and CoMSIA reveals novel insight towards inhibition of Bcr-Abl oncoprotein.
    San Juan AA
    J Mol Graph Model; 2007 Sep; 26(2):482-93. PubMed ID: 17446106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
    Yi P; Fang X; Qiu M
    Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
    Holder S; Lilly M; Brown ML
    Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CoMFA and docking studies of 2-phenylindole derivatives with anticancer activity.
    Liao SY; Qian L; Miao TF; Lu HL; Zheng KC
    Eur J Med Chem; 2009 Jul; 44(7):2822-7. PubMed ID: 19167135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three-dimensional quantitative structure: activity relationship studies on diverse structural classes of HIV-1 integrase inhibitors using CoMFA and CoMSIA.
    Nunthaboot N; Tonmunphean S; Parasuk V; Wolschann P; Kokpol S
    Eur J Med Chem; 2006 Dec; 41(12):1359-72. PubMed ID: 17002889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines.
    Nayyar A; Monga V; Malde A; Coutinho E; Jain R
    Bioorg Med Chem; 2007 Jan; 15(2):626-40. PubMed ID: 17107805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3D-QSAR CoMFA studies on bis-coumarine analogues as urease inhibitors: a strategic design in anti-urease agents.
    Zaheer-ul-Haq ; Lodhi MA; Ahmad Nawaz S; Iqbal S; Mohammed Khan K; Rode BM; Atta-ur-Rahman ; Choudhary MI
    Bioorg Med Chem; 2008 Mar; 16(6):3456-61. PubMed ID: 18280742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative molecular field analysis and comparative molecular similarity indices analysis of human thymidine kinase 1 substrates.
    Bandyopadhyaya AK; Johnsamuel J; Al-Madhoun AS; Eriksson S; Tjarks W
    Bioorg Med Chem; 2005 Mar; 13(5):1681-9. PubMed ID: 15698786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.